新型抗碳青霉烯类抗生素感染治疗方案。
New Treatment Options against Carbapenem-Resistant Infections.
机构信息
Istanbul Education and Research Hospital, Istanbul, Turkey.
University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
出版信息
Antimicrob Agents Chemother. 2018 Dec 21;63(1). doi: 10.1128/AAC.01110-18. Print 2019 Jan.
Abstract
Carbapenem-resistant (CRAB) is a perilous nosocomial pathogen causing substantial morbidity and mortality. Current treatment options for CRAB are limited and suffer from pharmacokinetic limitations, such as high toxicity and low plasma levels. As a result, CRAB is declared as the top priority pathogen by the World Health Organization for the investment in new drugs. This urgent need for new therapies, in combination with faster FDA approval process, accelerated new drug development and placed several drug candidates in the pipeline. This article reviews available information about the new drugs and other therapeutic options focusing on agents in clinical or late-stage preclinical studies for the treatment of CRAB, and it evaluates their expected benefits and potential shortcomings.
摘要
耐碳青霉烯类肠杆菌科细菌（CRAB）是一种危险的医院获得性病原体，可导致严重的发病率和死亡率。目前治疗 CRAB 的选择有限，并受到药代动力学限制，如高毒性和低血浆水平。因此，世界卫生组织宣布 CRAB 为需要投资新药的首要病原体。这种对新疗法的迫切需求，加上更快的 FDA 审批流程，加速了新药的开发，并使几种候选药物进入了研发管道。本文综述了有关新药和其他治疗选择的现有信息，重点介绍了治疗 CRAB 的临床或临床前后期研究中的药物，并评估了它们的预期益处和潜在缺陷。
相似文献
1
New Treatment Options against Carbapenem-Resistant Infections.新型抗碳青霉烯类抗生素感染治疗方案。
Antimicrob Agents Chemother. 2018 Dec 21;63(1). doi: 10.1128/AAC.01110-18. Print 2019 Jan.
2
Should we, and how to, optimize cefiderocol administration during severe nosocomial pneumonia due to carbapenem-resistant Acinetobacter baumanii? A viewpoint.我们是否应该以及如何优化碳青霉烯类耐药鲍曼不动杆菌引起的严重医院获得性肺炎时的头孢地尔的给药方案？一种观点。
J Glob Antimicrob Resist. 2024 Sep;38:140-145. doi: 10.1016/j.jgar.2024.05.014. Epub 2024 Jun 5.
3
Adaptations of carbapenem resistant (CRAB) in the hospital environment causing sustained outbreak.耐碳青霉烯类肠杆菌科细菌（CRAB）在医院环境中的适应性导致持续暴发。
J Med Microbiol. 2021 Mar;70(3). doi: 10.1099/jmm.0.001345. Epub 2021 Mar 19.
4
Phenotypic and molecular characterization of Acinetobacter baumannii isolates causing lower respiratory infections among ICU patients.分析 ICU 患者下呼吸道感染的鲍曼不动杆菌分离株的表型和分子特征。
Microb Pathog. 2019 Mar;128:75-81. doi: 10.1016/j.micpath.2018.12.023. Epub 2018 Dec 15.
5
Prospective role of cefiderocol in the management of carbapenem-resistant Acinetobacter baumannii infections: Review of the evidence.头孢地尔在碳青霉烯类耐药鲍曼不动杆菌感染管理中的前瞻性作用：证据回顾。
Int J Antimicrob Agents. 2023 Aug;62(2):106882. doi: 10.1016/j.ijantimicag.2023.106882. Epub 2023 Jun 8.
6
Risk factors and mortality of patients with nosocomial carbapenem-resistant Acinetobacter baumannii pneumonia.医院获得性耐碳青霉烯鲍曼不动杆菌肺炎患者的危险因素和死亡率。
Am J Infect Control. 2013 Jul;41(7):e59-63. doi: 10.1016/j.ajic.2013.01.006. Epub 2013 Mar 21.
7
Insights into the epidemiology, risk factors, and clinical outcomes of carbapenem-resistant infections in critically ill children.重症儿童耐碳青霉烯类感染的流行病学、危险因素和临床结局的研究进展。
Front Public Health. 2023 Nov 30;11:1282413. doi: 10.3389/fpubh.2023.1282413. eCollection 2023.
8
Prospective multi-center evaluation on risk factors, clinical characteristics and outcomes due to carbapenem resistance in complex bacteraemia: experience from the Chinese Antimicrobial Resistance Surveillance of Nosocomial Infections (CARES) Network.复杂血流感染碳青霉烯耐药的危险因素、临床特征和结局的前瞻性多中心评估：来自中国医院感染抗菌药物耐药监测网（CARES）的经验。
J Med Microbiol. 2020 Jul;69(7):949-959. doi: 10.1099/jmm.0.001222.
9
Treatment of infections caused by carbapenem-resistant .治疗耐碳青霉烯类抗生素的感染。
Front Cell Infect Microbiol. 2024 Jul 18;14:1395260. doi: 10.3389/fcimb.2024.1395260. eCollection 2024.
10
Induced Heteroresistance in Carbapenem-Resistant (CRAB) via Exposure to Human Pleural Fluid (HPF) and Its Impact on Cefiderocol Susceptibility.诱导耐碳青霉烯类抗生素鲍曼不动杆菌（CRAB）异质性耐药及其对头孢地尔洛敏感性的影响。
Int J Mol Sci. 2023 Jul 21;24(14):11752. doi: 10.3390/ijms241411752.
引用本文的文献
1
Resistance and heteroresistance as a consequence of colistin therapy during murine pneumonia.在小鼠肺炎期间，黏菌素治疗导致的耐药性和异质性耐药。
bioRxiv. 2025 Jul 24:2025.07.24.666669. doi: 10.1101/2025.07.24.666669.
2
The global epidemiology of carbapenem-resistant .耐碳青霉烯类药物的全球流行病学情况
JAC Antimicrob Resist. 2025 Jul 29;7(4):dlaf134. doi: 10.1093/jacamr/dlaf134. eCollection 2025 Aug.
3
Activity of ampicillin-sulbactam, sulbactam-durlobactam, and comparators against complex strains isolated from respiratory and bloodstream sources: results from ACNBio study.氨苄西林-舒巴坦、舒巴坦-度洛巴坦及对照药物对从呼吸道和血流来源分离出的复杂菌株的活性：ACNBio研究结果
Antimicrob Agents Chemother. 2025 Aug 6;69(8):e0037925. doi: 10.1128/aac.00379-25. Epub 2025 Jul 17.
4
Pharmacodynamic Evaluation of Adjuvant Targets: Low Molecular Weight PBP7/8 Effects on β-Lactam Activity Against Carbapenem-Resistant Acinetobacter Baumannii.辅助靶点的药效学评估：低分子量PBP7/8对β-内酰胺类药物抗耐碳青霉烯类鲍曼不动杆菌活性的影响
Pharmaceuticals (Basel). 2025 Jun 18;18(6):918. doi: 10.3390/ph18060918.
5
Hypervirulent (hvAB): The Convergence of Virulence and Multidrug Resistance.高毒力（hvAB）：毒力与多重耐药性的融合
Antibiotics (Basel). 2025 May 29;14(6):551. doi: 10.3390/antibiotics14060551.
6
Prevalence and characteristics of tigecycline- and carbapenem-resistant -truncated : a genomic epidemiological analysis.替加环素和碳青霉烯类耐药性截断的流行情况及特征：一项基因组流行病学分析
Antimicrob Agents Chemother. 2025 Jun 4;69(6):e0184324. doi: 10.1128/aac.01843-24. Epub 2025 Apr 23.
7
Arginine utilization in is essential for pneumonia pathogenesis and is regulated by virulence regulator GacA.精氨酸的利用在肺炎发病机制中至关重要，且受毒力调节因子GacA调控。
Infect Immun. 2025 May 13;93(5):e0057224. doi: 10.1128/iai.00572-24. Epub 2025 Apr 2.
8
Inhibitory Effect of Antimicrobial Peptides Bac7(17), PAsmr5-17 and PAβN on Bacterial Growth and Biofilm Formation of Multidrug-Resistant .抗菌肽Bac7(17)、PAsmr5 - 17和PAβN对多重耐药菌生长及生物膜形成的抑制作用
Microorganisms. 2025 Mar 11;13(3):639. doi: 10.3390/microorganisms13030639.
9
Carbapenem-resistant and Ventilator-associated Pneumonia; Epidemiology, Risk Factors, and Current Therapeutic Approaches.耐碳青霉烯类与呼吸机相关性肺炎：流行病学、危险因素及当前治疗方法
J Res Pharm Pract. 2024 Dec 23;13(2):33-40. doi: 10.4103/jrpp.jrpp_50_24. eCollection 2024 Apr-Jun.
10
Cyclic Peptide MV6, an Aminoglycoside Efficacy Enhancer Against .环肽MV6，一种针对……的氨基糖苷类增效剂
Antibiotics (Basel). 2024 Dec 1;13(12):1147. doi: 10.3390/antibiotics13121147.
本文引用的文献
1
Pharmacokinetic and Pharmacodynamic Considerations for the Use of Monoclonal Antibodies in the Treatment of Bacterial Infections.单克隆抗体用于治疗细菌感染的药代动力学和药效学考量
Antibodies (Basel). 2018 Jan 4;7(1):5. doi: 10.3390/antib7010005.
2
Phage Therapy for a Multidrug-Resistant Craniectomy Site Infection.噬菌体疗法治疗耐多药颅骨切除部位感染
Open Forum Infect Dis. 2018 Mar 23;5(4):ofy064. doi: 10.1093/ofid/ofy064. eCollection 2018 Apr.
3
Strategic Approaches to Overcome Resistance against Gram-Negative Pathogens Using β-Lactamase Inhibitors and β-Lactam Enhancers: Activity of Three Novel Diazabicyclooctanes WCK 5153, Zidebactam (WCK 5107), and WCK 4234.使用β-内酰胺酶抑制剂和β-内酰胺增强剂克服革兰氏阴性病原体耐药性的策略：三种新型二氮杂二环辛烷 WCK 5153、齐他培南（WCK 5107）和 WCK 4234 的活性。
J Med Chem. 2018 May 10;61(9):4067-4086. doi: 10.1021/acs.jmedchem.8b00091. Epub 2018 Apr 20.
4
Activity of TP-6076 against carbapenem-resistant Acinetobacter baumannii isolates collected from inpatients in Greek hospitals.TP-6076 对希腊医院住院患者分离的耐碳青霉烯鲍曼不动杆菌的活性。
Int J Antimicrob Agents. 2018 Aug;52(2):269-271. doi: 10.1016/j.ijantimicag.2018.03.009. Epub 2018 Mar 17.
5
Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial.多黏菌素单用与多黏菌素联合美罗培南治疗碳青霉烯类耐药革兰氏阴性菌引起的严重感染：一项开放标签、随机对照试验。
Lancet Infect Dis. 2018 Apr;18(4):391-400. doi: 10.1016/S1473-3099(18)30099-9. Epub 2018 Feb 16.
6
Phage Therapy as a Promising New Treatment for Lung Infection Caused by Carbapenem-Resistant in Mice.噬菌体疗法作为一种有前景的新型治疗方法用于治疗小鼠耐碳青霉烯类药物引起的肺部感染。
Front Microbiol. 2018 Jan 9;8:2659. doi: 10.3389/fmicb.2017.02659. eCollection 2017.
7
Efficacy of Apramycin against Multidrug-Resistant Acinetobacter baumannii in the Murine Neutropenic Thigh Model.安普霉素对中性粒细胞减少症小鼠大腿模型中多药耐药鲍曼不动杆菌的疗效。
Antimicrob Agents Chemother. 2018 Mar 27;62(4). doi: 10.1128/AAC.02585-17. Print 2018 Apr.
8
Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis.发现、研究和开发新抗生素：世界卫生组织抗微生物药物耐药性和结核病优先病原体清单。
Lancet Infect Dis. 2018 Mar;18(3):318-327. doi: 10.1016/S1473-3099(17)30753-3. Epub 2017 Dec 21.
9
Phage Abp1 Rescues Human Cells and Mice from Infection by Pan-Drug Resistant Acinetobacter Baumannii.噬菌体Abp1可使人类细胞和小鼠免受泛耐药鲍曼不动杆菌感染。
Cell Physiol Biochem. 2017;44(6):2337-2345. doi: 10.1159/000486117. Epub 2017 Dec 15.
10
Activity of the Siderophore Cephalosporin, Cefiderocol, against Carbapenem-Nonsusceptible and Multidrug-Resistant Isolates of Gram-Negative Bacilli Collected Worldwide in 2014 to 2016.2014 年至 2016 年全球范围内收集的碳青霉烯类药物不敏感和多重耐药革兰氏阴性杆菌的头孢菌素类抗生素头孢地尔的活性。
Antimicrob Agents Chemother. 2018 Jan 25;62(2). doi: 10.1128/AAC.01968-17. Print 2018 Feb.
Zotero 插件